The Shares You Buy Today In This Company For Under 50 Cents Could Explode 4,694% - As They Have Just Revealed "The Greatest Medical Discovery Of The 21st Century" That means an investment of just $5,000 blossoms into $239,726 - $10,000 soars into $479,452 - and this could all happen even before a high priced buyout by "Big Pharma" sends share prices up even higher! I'll prove below, why a buyout by Roche, Biogen or Pfizer, may be virtually guaranteed! 
Serious Stock Investor: What I'm about to reveal to you is the most important medical advance in the past 80 years. You'd have to go all the way back to 1928, back when Penicillin was discovered, to find something as big or as significant as this find! A5 Laboratories (ticker: AFLB) has invented a way to create interferon - one of the most crucial ingredients in drug therapy - and they're making it 100 times cheaper and potentially 100 to 1,000 times more effective than any competitor's product. But before we get into exactly how AFLB's discovery is going to make us rich, we need to answer that important question...  | What are interferons and why are they so important? Interferons are found natural in our bodies and are actually proteins made by your white blood cells. They perform a number of important immune functions such as fighting diseases or even cancer! Just a dip in the number of these important "life defenders", could make you very sick and can even lead to death. This is why interferons are so important to many life-saving drug therapies and why a change has to be made... Because what "Big Pharma" is using right now, is genetically engineered, often toxic, difficult to make, and incredibly expensive. And A5 Laboratories(AFLB) announcement of their astonishing new breakthrough has them poised to take over this 9 Billion market! |  | You see, they were able to create a completely non-toxic, natural, easy to manufacture and surprisingly inexpensive species-specific interferon that could turn the entire medical world on it's ear, and by doing so capturing 100% of the interferon market... That's right, 100%! This has never been done before! Best of all (especially for early shareholders) A5 Laboratories (ticker: AFLB) could very easily sell their superior interferon to virtually every major drug company for 1/7th the price of the current product used, while potentially posting profit margins in excess of 93%! And by being able to drop the price so dramatically, thousands of more companies may buy it, and thousands of new applications can be found for it... Soon, the interferon market could expand from $9 billion to $12 billion, then to $18 billion, and even to $27 billion! This $9 Billion market will belong to A5 Laboratories (AFLB). This isn't pie in the sky - Interferon is a proven valuable ingredient already approved and used in hundreds of drug formulations - many of them established blockbusters with annual sales in the $Billions. A5 Laboratories' natural interferon (ng-INF) - for which they have 3 patents pending and world-wide manufacturing rights - will revolutionize medical treatment, for both humans and animals, around the world. And get this... Virtually every pharmaceutical company, every biotech firm, and every university research lab will be beating A5's door down to get their superior interferon at 1/7th the current price! I don't have to tell what that'll mean to early share-holders who accumulate AFLB between $.75 and $1.50 now... Why Big Pharma Could Be
Circling AFLB As We Speak The fastest way to sales in the $billions (and windfall profits for A5 and its shareholders) is to license their superior ng-INF for use in already established blockbuster drugs. A5 could very well cut a lucrative licensing deal with Big Pharmaceutical companies, like Pfizer or Roche, to make and add ng-INF to their already successful products. Assuming A5's ng-INF makes these drugs far more effective, sales could easily double, or even triple as it becomes the drug of choice... And A5 will collect a percentage-of-sales royalty on the new formulation, bringing AFLB (and its shareholders) a whole new stream of revenue! But why would these companies cut a royalty deal with A5 Laboratories, when they've already have top-selling drugs? Well, one reason is they'll pay a lot less for the interferon. But the main reason is.. If they don't, their competition could cut a deal with A5, likely making their product so much better, that the "loser's" sales could dry up overnight, while the "winner's" sales double to $5 billion or more! And if Teva and Pfizer don't want to play ball, Biogen would love to add A5's ng-INF to its products, which might quadruple its current $1.7 billion annual sales to $6.8, while largely killing sales of Pfizer and Teva! Do you see why A5 Laboratories is my #1 bio tech pick of 2010? It's because one of these giant drug companies almost HAS to buy them out in order to cut out the competition completely! If you do only one thing for your future wealth today, it should be reading my full report on A5 Laboratories by SELECTING HERE. Mark my words, AFLB has the single greatest breakthrough in drug technology in my lifetime, and I'm calling AFLB my top Biotech pick lock of 2010 and beyond!! Do NOT MISS this one
Select here to read on Here's to solid investing, Tim Fields
Untapped Wealth
| 
No comments:
Post a Comment